Prognostic of Dysfunctional Breathing in Long Covid: a Follow up Study

COVID-19 Clinical Trial

Official title:

Prognostic of Dysfunctional Breathing in Long Covid: a Follow up Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05217875
• Other study ID #: 2021-01698
• Status: Recruiting
• Start date: November 1, 2021
• Est. completion date: August 2022

Study information

• Verified date: December 2021
• Source: Hôpital du Valais
• Contact: Pierre-Olivier v Bridevaux
• Phone: +41792079069
• Email: pierre-olivier.bridevaux[@]hopitalvs.ch
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Dysfunctional breathing might participate to dyspnoea in long COVID-19. This study investigate the prognosis of patients diagnosed with dysfunctional breathing after SARS-CoV-2 infection in our center.

Description:

Dysfunctional breathing (DB) with or without hyperventilation syndrome (HVS) as diagnosed using cardiopulmonary exercise test (CPET) was recently demonstrated as an important physiopathological mechanism of persistent dyspnoea in long COVID patients [1]. DB is characterized by specific ventilation pattern on CPET accompanied by respiratory discomfort and/or dyspnea at exercise [2]. Most patients with DB will have undergone some sort a specific physiotherapy retraining [3]. However the prognostic and the predictors of persistence/resolution of DB after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are unknown. The aim of the study is to determine the prognostic of patients diagnosed with DB after SARS-CoV-2 infection, as well as prognosis factors and predictors of persistence/resolution of DB during a prospective follow up visit.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: August 2022
• Est. primary completion date: June 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 14 Years and older

Eligibility

Inclusion Criteria:

• patients 14 years or more
• diagnosis of DB after SARS-CoV-2 at our long covid clinic using a combined approach of symptoms and CPET analysis in the hospitals of Sion, Martigny or Rennaz
• Inclusion between November 2020 and until the end of October 2021

Exclusion Criteria:

• Refusal to participate
• comorbidities preventing the CPET or PFT to be carried out

Related Conditions & MeSH terms

• COVID-19
• Dysfunctional Breathing
• Respiratory Aspiration

Locations

Country	Name	City	State
Switzerland	Centre hospitalier du valais romand	Martigny

Sponsors (1)

Lead Sponsor	Collaborator
Hôpital du Valais

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Persistence/resolution of dysfunctional breathing at follow-up visit	defined by persistence/resolution of dyspnea, as compared with patient's baseline (equivalent level of dyspnea as before COVID-19).	6 to 9 monts from diagnosis
Secondary	Change in ventilatory patterns (tidal volume [VT], breathing frequency [BF] at isowork as compared with baseline		6 to 9 monts from diagnosis
Secondary	Dispersion of VT and BF during the CPET		6 to 9 monts from diagnosis
Secondary	Change in ETCO2 and PaCO2		6 to 9 monts from diagnosis
Secondary	Qualitative changes (increase/decrease/no change of DB pattern of CPET)		6 to 9 monts from diagnosis
Secondary	Score HADS changes		6 to 9 monts from diagnosis
Secondary	Score SF-36 changes		6 to 9 monts from diagnosis
Secondary	Specific symptom scale changes		6 to 9 monts from diagnosis
Secondary	Specific work capacity changes questions		6 to 9 monts from diagnosis
Secondary	Post-COVID Functional Status (PCFS) changes		6 to 9 monts from diagnosis